Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

An ethics complaint leads to a resignation, and the agency shifts approval standards.

Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance ...

Dr George Tidmarsh resigned after he was placed on administrative leave during an investigation into comments he made about a drug.

In other news, the FDA moves to restrict use of fluoride supplements by children and the EPA approves more pesticides that some consider PFAS ...

On Friday, UroGen Pharma URGN got a positive adjustment to its Relative Strength (RS) Rating, from 90 to 96. Please watch the ...

Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure ...

Aurinia Pharmaceuticals Inc. (AUPH) has recently garnered a “Buy” rating from Jefferies analyst Maury Raycroft, a change that could have significant implications for investors. With a target price of ...

Black Hills Corporation (BKH) received an attractive rating upgrade from Andrew Weisel at Scotiabank, who designated the utility firm a “Sector Outperform.” This bullish outlook projects a price ...